Polaryx Therapeutics, Inc. · NASDAQ:PLYX

Polaryx Therapeutics, Inc. financial statements

Polaryx Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Research and development6.27M2.81M2.77M
Selling, general and administrative1.55M1.54M1.01M
Operating income-7.82M-4.35M-3.78M
Income before tax-8.98M-30.4M-3.78M
Net income-8.98M-30.4M-3.78M
Earnings per share, basic-0.20-0.89-0.02
Earnings per share, diluted-0.20-0.89

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents5.14M4.62M2.00K
Current assets5.17M5.00M2.31M
Total assets5.17M5.00M2.31M
Accounts payable470.0K72.0K473.0K
Current liabilities605.0K289.0K1.04M
Total debt128.0K
Total liabilities605.0K289.0K1.04M
Shareholders' equity4.57M4.71M1.28M
Shares outstanding47.3M41.2M189.4M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-3.94M-2.57M-173.0K
Capital spending000
Free cash flow-3.94M-2.57M-173.0K
Cash from financing4.47M7.19M128.0K
Change in cash522.0K4.62M-45.0K